These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24170263)

  • 41. Absorption and elimination of imatinib through the rat intestine in vitro.
    Kralj E; Zakelj S; Trontelj J; Roškar R; Cernelč P; Kristl A
    Int J Pharm; 2014 Jan; 460(1-2):144-9. PubMed ID: 24219857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Ma P; Peng B; Verweij J; Racine A; di Paola ED; van Glabbeke M; Dimitrijevic S; Scurr M; Dumez H; van Oosterom A
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):379-386. PubMed ID: 15592836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
    Declèves X; Bihorel S; Debray M; Yousif S; Camenisch G; Scherrmann JM
    Pharmacol Res; 2008 Mar; 57(3):214-22. PubMed ID: 18337118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
    Turjap M; Juřica J; Demlová R
    Klin Onkol; 2015; 28(2):105-11. PubMed ID: 25882020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
    De Francia S; DʼAvolio A; Ariaudo A; Pirro E; Piccione F; Simiele M; Fava C; Calcagno A; Di Perri G; Saglio G
    Ther Drug Monit; 2014 Jun; 36(3):410-2. PubMed ID: 24342895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
    Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical pharmacokinetics of imatinib.
    Peng B; Lloyd P; Schran H
    Clin Pharmacokinet; 2005; 44(9):879-94. PubMed ID: 16122278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].
    Xu H; Ma L; Xu W; Guan W; Wang B; Li G; Miao Y; Li L; Chen H; Yu J; Wang Y; Sun L; Yang L; Zhang D; Li F; Zhi X; Wang J; Xu J; Xu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1271-1276. PubMed ID: 27928798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
    Parise RA; Ramanathan RK; Hayes MJ; Egorin MJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):39-44. PubMed ID: 12798163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.
    Kim DW; Tan EY; Jin Y; Park S; Hayes M; Demirhan E; Schran H; Wang Y
    Br J Clin Pharmacol; 2011 Feb; 71(2):199-206. PubMed ID: 21219400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
    Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
    Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    Kelley RK; Hwang J; Magbanua MJ; Watt L; Beumer JH; Christner SM; Baruchel S; Wu B; Fong L; Yeh BM; Moore AP; Ko AH; Korn WM; Rajpal S; Park JW; Tempero MA; Venook AP; Bergsland EK
    Br J Cancer; 2013 Oct; 109(7):1725-34. PubMed ID: 24022191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?
    von Mehren M; Widmer N
    Cancer Treat Rev; 2011 Jun; 37(4):291-9. PubMed ID: 21078547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
    Connolly RM; Rudek MA; Garrett-Mayer E; Jeter SC; Donehower MG; Wright LA; Zhao M; Fetting JH; Emens LA; Stearns V; Davidson NE; Baker SD; Wolff AC
    Breast Cancer Res Treat; 2011 May; 127(1):153-62. PubMed ID: 21350820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
    Burger H; Mathijssen RH; Sparreboom A; Wiemer EA
    Blood; 2013 Jun; 121(24):4965-6. PubMed ID: 23766461
    [No Abstract]   [Full Text] [Related]  

  • 60. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
    Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.